Long COVID and gut microbiome: insights into pathogenesis and therapeutics
Post-acute coronavirus disease 2019 syndrome (PACS), following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19), is typically characterized by long-term debilitating symptoms affecting multiple organs and systems. Unfortunately, there is c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2025.2457495 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587251607928832 |
|---|---|
| author | Raphaela I. Lau Qi Su Siew C. Ng |
| author_facet | Raphaela I. Lau Qi Su Siew C. Ng |
| author_sort | Raphaela I. Lau |
| collection | DOAJ |
| description | Post-acute coronavirus disease 2019 syndrome (PACS), following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19), is typically characterized by long-term debilitating symptoms affecting multiple organs and systems. Unfortunately, there is currently a lack of effective treatment strategies. Altered gut microbiome has been proposed as one of the plausible mechanisms involved in the pathogenesis of PACS; extensive studies have emerged to bridge the gap between the persistent symptoms and the dysbiosis of gut microbiome. Recent clinical trials have indicated that gut microbiome modulation using probiotics, prebiotics, and fecal microbiota transplantation (FMT) led to improvements in multiple symptoms related to PACS, including fatigue, memory loss, difficulty in concentration, gastrointestinal upset, and disturbances in sleep and mood. In this review, we highlight the latest evidence on the key microbial alterations observed in PACS, as well as the use of microbiome-based therapeutics in managing PACS symptoms. These novel findings altogether shed light on the treatment of PACS and other chronic conditions. |
| format | Article |
| id | doaj-art-dce73145df4e4abf8034984458cf3edb |
| institution | Kabale University |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-dce73145df4e4abf8034984458cf3edb2025-01-24T17:01:40ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2025.2457495Long COVID and gut microbiome: insights into pathogenesis and therapeuticsRaphaela I. Lau0Qi Su1Siew C. Ng2Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, ChinaPost-acute coronavirus disease 2019 syndrome (PACS), following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19), is typically characterized by long-term debilitating symptoms affecting multiple organs and systems. Unfortunately, there is currently a lack of effective treatment strategies. Altered gut microbiome has been proposed as one of the plausible mechanisms involved in the pathogenesis of PACS; extensive studies have emerged to bridge the gap between the persistent symptoms and the dysbiosis of gut microbiome. Recent clinical trials have indicated that gut microbiome modulation using probiotics, prebiotics, and fecal microbiota transplantation (FMT) led to improvements in multiple symptoms related to PACS, including fatigue, memory loss, difficulty in concentration, gastrointestinal upset, and disturbances in sleep and mood. In this review, we highlight the latest evidence on the key microbial alterations observed in PACS, as well as the use of microbiome-based therapeutics in managing PACS symptoms. These novel findings altogether shed light on the treatment of PACS and other chronic conditions.https://www.tandfonline.com/doi/10.1080/19490976.2025.2457495Long COVIDpost-acute COVID-19 syndromegut microbiomemicrobiome-based therapeutics |
| spellingShingle | Raphaela I. Lau Qi Su Siew C. Ng Long COVID and gut microbiome: insights into pathogenesis and therapeutics Gut Microbes Long COVID post-acute COVID-19 syndrome gut microbiome microbiome-based therapeutics |
| title | Long COVID and gut microbiome: insights into pathogenesis and therapeutics |
| title_full | Long COVID and gut microbiome: insights into pathogenesis and therapeutics |
| title_fullStr | Long COVID and gut microbiome: insights into pathogenesis and therapeutics |
| title_full_unstemmed | Long COVID and gut microbiome: insights into pathogenesis and therapeutics |
| title_short | Long COVID and gut microbiome: insights into pathogenesis and therapeutics |
| title_sort | long covid and gut microbiome insights into pathogenesis and therapeutics |
| topic | Long COVID post-acute COVID-19 syndrome gut microbiome microbiome-based therapeutics |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2025.2457495 |
| work_keys_str_mv | AT raphaelailau longcovidandgutmicrobiomeinsightsintopathogenesisandtherapeutics AT qisu longcovidandgutmicrobiomeinsightsintopathogenesisandtherapeutics AT siewcng longcovidandgutmicrobiomeinsightsintopathogenesisandtherapeutics |